This multicenter, prospective, real-world study will consecutively enroll moderate to severe plaque psoriasis adult patients who are anticipated to receive xeligekimab for the first time. All patients will receive routine clinical care. The study will evaluate the treatment's effectiveness and safety and observe treatment patterns for up to 52 weeks.
Objectives:
Primary Objective:
To evaluate the effectiveness and safety of xeligekimab in adult patients with moderate to severe plaque psoriasis in clinical practice.
Secondary Objective:
To observe the treatment patterns of xeligekimab in adult patients with moderate to severe plaque psoriasis in clinical practice.
Exploratory Objectives:
* To explore the effectiveness of xeligekimab in subgroup patients with psoriatic arthritis.
* To explore the effectiveness of xeligekimab in subgroup patients with psoriasis involving special areas (scalp, nails, palmoplantar areas, genital areas, etc.).
* To explore the effectiveness of xeligekimab in subgroup patients with comorbidities of psoriasis.
* To explore the effectiveness and safety of xeligekimab in subgroup patients with psoriasis who have previously received treatment with other biologic agents.
